4283 completed. 4283 Phase 1, 818 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4283 | Completed 4283 |
| Phase 2 | 818 | Completed 818 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years Midazolam (MDZ), GSK3772701 - Malaria, Falciparum | Phase 1 | Completed | GlaxoSmithKline | 20 | 2026-06-26 | 2026-09-30 |
| A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet - Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19) | Phase 1 | Completed | Pfizer | 17 | 2026-04-13 | 2026-07-28 |
| Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions ACC118-Test, Reference - Human Immunodeficiency Virus (HIV) Infection | Phase 1 | Completed | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 48 | 2026-04-10 | 2026-08-10 |
| Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function Pevifoscorvir Sodium (ALG-000184) - Chronic Hepatitis B Infection | Phase 1 | Completed | Aligos Therapeutics | 12 | 2026-03-10 | 2026-08-21 |
| Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects DA-2902, DA-2902-R - Infective Disorder | Phase 1 | Completed | Dong-A ST Co., Ltd. | 40 | 2025-11-07 | 2026-06-02 |
| A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults Ibuzatrelvir - Healthy Participant | Phase 1 | Completed | Pfizer | 12 | 2025-10-16 | 2026-01-07 |
| A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers. BAY 3389934, Matching Placebo / Diluent - Sepsis Associated Disseminated Intravascular Coagulation (DIC) | Phase 1 | Completed | Bayer | 16 | 2025-09-22 | 2026-06-05 |
| A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment Cefiderocol/Xeruborbactam - Bacterial Infections | Phase 1 | Completed | Qpex Biopharma, Inc. | 40 | 2025-09-16 | 2026-09-25 |
| Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose) Influenza Vaccine (Split Virion), Inactivated (High Dose), Influenza Vaccine (Split Virion), Inactivated - Influenza | Phase 1 | Completed | Sinovac Biotech Co., Ltd | 50 | 2025-08-21 | 2026-09-23 |
| A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial | Phase 1 | Completed | GlaxoSmithKline | 127 | 2025-08-12 | 2026-06-05 |
| Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults STX-S - COVID-19 | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2025-08-11 | 2026-06-26 |
| First-in-Human Trial of Oral AN2-502998 AN2-502998, Placebo - Healthy Volunteers | Phase 1 | Completed | AN2 Therapeutics, Inc | 72 | 2025-08-04 | 2026-04-30 |
| Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso SUM-101 - Malaria,Falciparum | Phase 1 | Completed | European Vaccine Initiative | 39 | 2025-08-01 | 2026-09-11 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2025-07-23 | 2026-08-17 |
| Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum) | Phase 1 | Completed | Centre de Recherche Médicale de Lambaréné | 20 | 2025-07-18 | 2026-09-11 |
| Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age RSV vaccine formulation 1 dose, RSV vaccine formulation 2 dose, RSV vaccine formulation 3 dose - Respiratory Syncytial Virus Immunization | Phase 1 | Completed | Sanofi | 240 | 2025-07-14 | 2026-04-28 |
| MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) MK-4646 - HIV Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2025-07-09 | 2026-06-22 |
| A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults VH4524184, Itraconazole, Rifabutin - HIV Infections | Phase 1 | Completed | ViiV Healthcare | 126 | 2025-07-07 | 2026-03-09 |
| A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults 20vPnC, 13vPnC - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 400 | 2025-07-06 | 2026-02-25 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
Showing 20 of 4283. Sign in to see all of them.
HIV Infections (857) · Acquired Immunodeficiency Syndrome (413) · COVID-19 (380) · Influenza, Human (333) · Hepatitis C (235) · Malaria (222) · Burkitt Lymphoma (215) · Lymphoma, Large B-Cell, Diffuse (177) · Lymphoma, Follicular (171) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (170) · Lymphoma, Mantle-Cell (169) · Lymphoma, Non-Hodgkin (160) · Leukemia, Lymphocytic, Chronic, B-Cell (153) · Lymphoma, B-Cell, Marginal Zone (153)
Virus Diseases (2898) · RNA Virus Infections (2383) · Communicable Diseases (1521) · Blood-Borne Infections (1472) · Immune System Diseases (1330) · Urogenital Diseases (1225) · Genital Diseases (1167) · Sexually Transmitted Diseases (1086) · Sexually Transmitted Diseases, Viral (1083) · Immunologic Deficiency Syndromes (1054) · Retroviridae Infections (1052) · Lentivirus Infections (1049) · Respiratory Tract Diseases (952) · Respiratory Tract Infections (838)
Ritonavir (89) · Sodium Chloride (69) · Zidovudine (66) · Saline Solution (61) · Influenza Vaccines (45) · Vaccines (38) · dolutegravir (37) · Midazolam (36) · Cyclophosphamide (32) · Aluminum Hydroxide (31) · Ribavirin (31) · Didanosine (29) · Tenofovir (29) · Lamivudine (28) · efavirenz (28)
National Institute of Allergy and Infectious Diseases (NIAID) (699) · GlaxoSmithKline (179) · ViiV Healthcare (103) · University of Oxford (92) · Merck Sharp & Dohme LLC (85) · National Cancer Institute (NCI) (83) · Pfizer (79) · U.S. Army Medical Research and Development Command (51) · Bristol-Myers Squibb (50) · Medicines for Malaria Venture (37) · Tibotec Pharmaceuticals, Ireland (37) · Sanofi Pasteur, a Sanofi Company (34) · Gilead Sciences (32) · Hoffmann-La Roche (29) · Radboud University Medical Center (28)
United States (2333) · United Kingdom (269) · China (212) · Australia (162) · Belgium (117) · Germany (111) · Canada (109) · South Africa (101) · Puerto Rico (85) · South Korea (84) · France (83) · Netherlands (79) · Spain (67) · Thailand (61) · Brazil (56)
Anna Durbin, MD (30) · Ruth A. Karron, MD (17) · Helen McShane (15) · Belshe R (9)
PMID 34473343, PMID 40190112, PMID 25820067, PMID 23349878, PMID 25466778, PMID 34817414, PMID 34843602, PMID 35713300, PMID 37231296, PMID 39787798, PMID 22288567, PMID 26383952, PMID 26432909, PMID 27568215, PMID 29217375, PMID 32838558, PMID 34895272, PMID 35769034, PMID 36147329, PMID 36435633, PMID 37781954, PMID 40245769, PMID 41014333, PMID 16148846, PMID 16220994, PMID 17957238, PMID 18090046, PMID 19118378, PMID 19529780, PMID 19540952, PMID 19949018, PMID 20028764, PMID 20126394, PMID 20629533, PMID 21488067, PMID 21906647, PMID 21975270, PMID 22002018, PMID 22242162, PMID 22306375, PMID 22336878, PMID 22426327, PMID 22542645, PMID 22900504, PMID 22914365, PMID 23526949, PMID 23899517, PMID 23979737, PMID 24260259, PMID 25114140
2015 (22), 2016 (21), 2009 (16), 2014 (16), 2019 (15), 2017 (14), 2008 (13), 2018 (13), P30CA033572 (8), 2023 (7), U01CA097452 (6), P30CA006973 (5), U01CA062487 (5), U01CA062502 (5), U01CA099168 (5)